90 related articles for article (PubMed ID: 20308003)
1. TGFbeta1 genetic polymorphism is associated with survival in head and neck squamous cell carcinoma independent of the severity of chemoradiotherapy induced mucositis.
Lundberg M; Saarilahti K; Mäkitie AA; Mattila PS
Oral Oncol; 2010 May; 46(5):369-72. PubMed ID: 20308003
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor beta 1 genotype and p16 as prognostic factors in head and neck squamous cell carcinoma.
Lundberg M; Leivo I; Saarilahti K; Mäkitie AA; Mattila PS
Acta Otolaryngol; 2012 Sep; 132(9):1006-12. PubMed ID: 22667340
[TBL] [Abstract][Full Text] [Related]
3. Association between transforming growth factor beta1 genetic polymorphism and response to chemoradiotherapy in head and neck squamous cell cancer.
Lundberg M; Pajusto M; Koskinen WJ; Mäkitie AA; Aaltonen LM; Mattila PS
Head Neck; 2009 May; 31(5):664-72. PubMed ID: 19260117
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
[TBL] [Abstract][Full Text] [Related]
5. Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma.
Porceddu SV; Campbell B; Rischin D; Corry J; Weih L; Guerrieri M; Grossi M; Peters LJ
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):365-73. PubMed ID: 15380568
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
[TBL] [Abstract][Full Text] [Related]
7. Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study.
Gouvêa de Lima A; Villar RC; de Castro G; Antequera R; Gil E; Rosalmeida MC; Federico MH; Snitcovsky IM
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):270-5. PubMed ID: 21163585
[TBL] [Abstract][Full Text] [Related]
8. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium.
Hainsworth JD; Spigel DR; Greco FA; Shipley DL; Peyton J; Rubin M; Stipanov M; Meluch A
Cancer J; 2011; 17(5):267-72. PubMed ID: 21952273
[TBL] [Abstract][Full Text] [Related]
9. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and toxicity of two dose levels of cisplatin/5-fluorouracil as the chemoradiotherapy regimen for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Su NW; Leu YS; Lee JC; Chen YJ; Chen HW; Liu CJ; Chang YF
Acta Otolaryngol; 2011 Dec; 131(12):1333-40. PubMed ID: 22017375
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer.
Fury MG; Lee NY; Sherman E; Lisa D; Kelly K; Lipson B; Carlson D; Stambuk H; Haque S; Shen R; Kraus D; Shah J; Pfister DG
Cancer; 2012 Oct; 118(20):5008-14. PubMed ID: 22415650
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
[TBL] [Abstract][Full Text] [Related]
13. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
Ghadjar P; Simcock M; Studer G; Allal AS; Ozsahin M; Bernier J; Töpfer M; Zimmermann F; Betz M; Glanzmann C; Aebersold DM;
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):524-31. PubMed ID: 21300466
[TBL] [Abstract][Full Text] [Related]
14. Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Shinoto M; Shioyama Y; Sasaki T; Nakamura K; Ohura H; Toh Y; Higaki Y; Yamaguchi T; Ohnishi K; Atsumi K; Hirata H; Honda H
Am J Clin Oncol; 2011 Aug; 34(4):362-6. PubMed ID: 20686402
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166
[TBL] [Abstract][Full Text] [Related]
17. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
[TBL] [Abstract][Full Text] [Related]
18. Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
Karakaya E; Yetmen O; Oksuz DC; Dyker KE; Coyle C; Sen M; Prestwich RJ
Oral Oncol; 2013 Jan; 49(1):55-9. PubMed ID: 22858313
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of head and neck squamous cell carcinoma patients with N3 neck disease treated primarily with chemoradiation versus surgical resection.
Smyth JK; Deal AM; Huang B; Weissler M; Zanation A; Shores C
Laryngoscope; 2011 Sep; 121(9):1881-7. PubMed ID: 21997727
[TBL] [Abstract][Full Text] [Related]
20. High-grade acute organ toxicity as positive prognostic factor in adjuvant radiation and chemotherapy for locally advanced head and neck cancer.
Wolff HA; Daldrup B; Jung K; Overbeck T; Hennies S; Matthias C; Hess CF; Roedel RM; Christiansen H
Radiology; 2011 Mar; 258(3):864-71. PubMed ID: 21339350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]